Title |
FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin®added to standard therapy in patients with lung cancer
|
---|---|
Published in |
BMC Cancer, October 2009
|
DOI | 10.1186/1471-2407-9-355 |
Pubmed ID | |
Authors |
Gareth O Griffiths, Sarah Burns, Simon I Noble, Fergus R Macbeth, David Cohen, Timothy S Maughan |
Abstract |
Venous thromboembolism (VTE) occurs when blood clots in the leg, pelvic or other deep vein (deep vein thrombosis) with or without transport of the thrombus into the pulmonary arterial circulation (pulmonary embolus). VTE is common in patients with cancer and is increased by surgery, chemotherapy, radiotherapy and disease progression. Low molecular weight heparin (LMWH) is routinely used to treat VTE and some evidence suggests that LMWH may also have an anticancer effect, by reduction in the incidence of metastases. The FRAGMATIC trial will assess the effect of adding dalteparin (FRAGMIN), a type of LMWH, to standard treatment for patients with lung cancer. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Jamaica | 1 | <1% |
United Kingdom | 1 | <1% |
France | 1 | <1% |
Unknown | 118 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 18 | 15% |
Student > Bachelor | 16 | 13% |
Researcher | 15 | 12% |
Student > Ph. D. Student | 10 | 8% |
Student > Doctoral Student | 8 | 7% |
Other | 22 | 18% |
Unknown | 32 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 41 | 34% |
Nursing and Health Professions | 13 | 11% |
Psychology | 8 | 7% |
Agricultural and Biological Sciences | 7 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
Other | 13 | 11% |
Unknown | 33 | 27% |